Fernando Cruz-Guilloty
Director - Oncology Precision Medicine & Lung Franchise Lead Johnson & Johnson
Fernando Cruz-Guilloty, is the Director, Oncology – Precision Medicine & Diagnostics at Janssen R&D. As the Amivantamab Franchise Lead, Fernando oversees the overarching Diagnostics (Dx) strategy for the Amivantamab/Rybrevant (EGFR-MET bi-specific Ab) program in biomarker-selected populations of Non-Small Cell Lung Cancer (NSCLC) and other solid tumors, including CRC and HNSCC.
He collaborates with key stakeholders, develops and executes precision medicine strategies to enable registration of pharmaceutical assets, leading a high-performing cross-functional team.
Seminars
Thursday 5th February 2026
Panel Discussion: Accelerating the Use of MRD as a Surrogate Endpoint Across Indications
9:30 am
- Leveraging existing MRD evidence from hematology (e.g. multiple myeloma) to inform regulatory and policy pathways in new settings
- Driving alignment on assays, thresholds, endpoints, and timepoints to ensure cross-study comparability and reproducibility
- Building collaborative frameworks and secure data-sharing models to generate the robust evidence required by regulators and payers
